Correlation between serum levels of RANKL with Cardiac abnormalities in Thalassemia Major Patients

Document Type : Research Paper


1 MSc of Hematology and Blood Banking, Mashhad University of Medical Sciences

2 Associate professor of pediatric Hematology & Oncology, Mashhad University of Medical Sciences

3 Professor of Pediatric Cardiology, Mashhad University of Medical Sciences

4 Cancer molecular pathology research center, Mashhad University of Medical Sciences


Background: Beta thalassemia is an autosomal, recessive disorder, characterized by ineffective erythropoiesis. Chronic transfusions and inability of body to eliminate iron lead to an iron overload, thereby causing damage to heart. The pathways implicated in iron-mediated heart diseases are reactive oxygen species (ROS) and receptor activator of nuclear factor kappa-B(RANK)/receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis-mediated inflammation. The aim of the study was to investigate serum level RANKL in left ventricular Hypertrophy (LVH), diastolic dysfunction Ejection fraction (EF), Pulmonary Artery Pressure (PAP)and MRIT*2 in thalassemia major patient.
Method: eighty two β-thalassemia patients older than 10 years were enrolled for the study. Two-dimensional and M-mode echocardiography analysis and MRIT2 was done in all patients. Serum RANKL levels were estimated by ELISA. Statistical analysis was performed with spss20.
Results: Mean age of patients was 23.69±6.83 years. LVH and diastolic dysfunction was present in 24 (29.30%) and 23 (28%) patients, respectively. There were no association's serum RANKL with diastolic dysfunction, LVH Ejection fraction (EF), Pulmonary Artery Pressure (PAP) and MRIT*2 were observed.
Conclusion: Cardiac involvement in this disease does not appear to depend on RANKL
serum level.


1.Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. β-thalassemia
cardiomyopathy: history, present considerations, and future perspectives. Circulation: Heart Failure. 2010;3(3):451-8.
2.Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological
surveys. Scientific reports. 2017 Apr 19;7(1):920. PubMed PMID: 28424478. Pubmed Central PMCID: PMC5430438.
Epub 2017/04/21. Eng
3.Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in β-thalassemia syndromes: a decade of
progress. The American journal of medicine. 2005;118(9):957-6
4.Malik S, Syed S, Ahmed N. Complications in transfusion–dependent patients of ß-thalassemia major: A review. Pak J
Med Sci. 2009;25(4):678-8
. 5.Rohani A, Akbari V, Moradipoor M, Akbartabar M. Prevalence of heart failure in the Cases of betathalassemia major; two years follow-up. Journal of Cardio-Thoracic Medicine. 2013;1(1):16-
6.Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the
RANKL/RANK/OPG system be a marker of plaque instability? Clinical and Developmental Immunology. 2007;2007
7.Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, et al. Soluble receptor activator of nuclear factor-kB
ligand and risk for cardiovascular disease. Circulation. 2007;116(4):385-91
8.Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL:
involvement in the orchestration of pathophysiological bone remodeling. Cytokine & growth factor reviews.
9.Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation. 1969;39(4):503-15.
10.Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D ,et al. β-thalassemia
cardiomyopathy: history, present considerations, and future perspectives. Circulation: Heart Failure. 2010;3(3):451-8
11. Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today–
prediction, prevention and management. European journal of haematology. 2008;80(2):93-10.6
12.Bosi G, Crepaz R, Gamberini M, Fortini M, Scarcia S, Bonsante E, et al. Left ventricular remodelling, and systolic
and diastolic function in young adults with β thalassaemia major: a Doppler echocardiographic assessment and
correlation with haematological data. Heart. 2003;89(7):762-6
13.Kattel S, Memon S, Saito K, Narula J, Saito Y. An effect of left ventricular hypertrophy on mild-to-moderate left
ventricular diastolic dysfunction. Hellenic Journal of Cardiology. 2016;57(2):92-8
14.Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in β-thalassemia major: a
cause of heart failure. Circulation. 1995;91(1):66-71
15.Du Z-D, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major.
American heart journal. 1997;134(3):532-7.
16.Derchi G, Fonti A, Forni GL, Galliera E, Cappellini MD, Turati F. Pulmonary hypertension in patients with
thalassemia major. American heart journal. 1999;138(2 Pt 1):384.
17.Moghaddam HM, Badiei Z, Eftekhari K, Shakeri R, Farhangi H. Prevalence of Pulmonary Hypertension in Patients
with Thalassemia Intermedia in 2009: a single center's experience. Electronic physician. 2015 Jul;7(3):1102-7. PubMed
PMID: 26388975. Pubmed Central PMCID: PMC4574695. Epub 2015/09/22. Eng
18.Rashidi F, Sate H, Mohammadi A, Koohi A, Nejati B, Naybzadeh A. Echocardiographic evaluation of prevalence of
pulmonary hypertension in beta-thalassemia major: A cross sectional study. Pediatric hematology and oncology. 2018
Aug - Sep;35(5-6):322-30. PubMed PMID: 30468099. Epub 2018/11/24. eng.
19.Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: A literature review. Journal of
International Medical Research. 2016;44(1):15-29.
20 Panizo S, Cardus A, Encinas.M, Parisi E, Valcheva P, López-Ongil S, et al. RANKL increases vascular smooth
muscle cell calcification through a RANK-BMP4–dependent pathway. Circulation research. 2009;104(9):1041-8.
21.Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of
bone matrix regulatory proteins in human atherosclerotic plaques. Arteriosclerosis, thrombosis, and vascular biology.
22.Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O ,et al. Enhanced T-cell expression of RANK
ligand in acute coronary syndrome: possible role in plaque destabilization. Arteriosclerosis, thrombosis, and vascular
biology. 2006;26(4):857-63
23. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, et al. Dysregulated osteoprotegerin/RANK
ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111(19):2461-8.
24.Wei T, Wang M, Wang M, Gan LY, Li X. Relationship of sRANKL level and vascular calcification score to
cardiovascular events in maintenance hemodialysis patients. Blood purification. 2009;28(4):342-5. PubMed PMID:
19729902. Epub 2009/09/05. Eng
25.Giaginis C, Papadopouli A, Zira A, Katsargyris A, Klonaris C, Theocharis S. Correlation of plasma osteoprotegerin
(OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with
advanced carotid atherosclerosis. Medical science monitor: international medical journal of experimental and clinical
research. 2012;18:)01(CR597.
26.Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore C. Relationships between osteoprotegerin,
receptor activator of the nuclear factor kB ligand and serum levels and carotid intima-media thickness in patients with
type 2 diabetes mellitus. Panminerva medica. 2014;56(3):221-5
27.Higgins CL, Isbilir S, Basto P, Chen IY, Vaduganathan M, Vaduganathan P, et al. Distribution of alkaline
phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma. The protein journal.
28.Loncar G, Bozic B, Cvorovic V, Radojicic Z, Dimkovic S, Markovic N, et al. Relationship between RANKL and
neuroendocrine activation in elderly males with heart failure. Endocrine. 2010 Feb;37(1):148-56. PubMed PMID:
20963564. Epub 2010/10/22. eng